Response to April 12, 2005, Office Action

Serial No.: 09/816,876

Filed: March 23, 2001

REMARKS

Claims 49-53, 54-57, and 99 are pending. Claims 58, 59,

and 95-104 have been cancelled without prejudice to their

prosecution in continuing applications.

Applicants thank the Examiner for renumbering claims 94-

104.

Claims 49-59, 59, and 94-104 stand rejected under 35 U.S.C.

\$112, first paragraph, as lacking enablement. In particular,

arguest that the specification only enables Examiner

treatment of Alzheimer's disease. Applicants respectfully

disagree but, solely to expedite prosecution of the application,

have amended the claims to pertain only to Alzheimer's disease.

These amendments overcome the § 112 rejection.

Claims 95-104 stand rejected under the judicially created

doctrine of obviousness-type double patenting in view of claims

12 and 13 of U.S. Patent number 6,737,420. Applicant's

cancellation of claims 95-104 overcomes this rejection.

Applicants respectfully submit that all requirements of

patentability have been met. Allowance of the claims and

passage of the case to issue are therefore respectfully

solicited.

-23-

E > 6

Response to April 12, 2005, Office Action

Serial No.: 09/816,876 Filed: March 23, 2001

Should the Examiner believe a discussion of this matter would be helpful, she is invited to telephone the undersigned at (312) 913-2136.

Ochber 12, 200 By:

Dated

Respectfully submitted,

Steven J. Sarussi Reg. No. 32,784

McDonnell Boehnen Hulbert & Berghoff LLP 300 S. Wacker Drive Chicago, IL 60606 (312) 913-0001